当前位置:首页 >> 产品展示 >> 橡塑 >> 橡胶原料 >>TPEE 日本东丽 6347A
TPEE 日本东丽 6347A放大图片

产品价格:面议   元(人民币)
上架日期:2017年5月10日
产地:荷兰
发货地:东莞  (发货期:当天内发货)
供应数量:不限
最少起订:1KG
浏览量:20
  暂无相关下载
其他资料下载:

         
东莞市广业塑胶原料有限公司

点击这里给我发消息
  详细说明  
品牌:日本东丽产地:荷兰
价格:面议人民币/KG规格:25KG/包

简要说明:TPEE 日本东丽 6347A 诚信经营,支持物流,快递和货运 电话:13412886878 邓生

详细介绍:

  

TPEE 日本东丽 6347A,价格合理,诚信经营,可全国供货(广东省内免费送上门)。支持物流,快递和货运;支持现金,银行转账交易。

东莞市广业塑胶原料有限公司专业销售原装进口塑胶原料,原厂原包,假一赔十,本司货源稳定充足,发货准时,交期和质量均有保障!是专业塑胶原料供应商!!!可提供COA,SMDS,SGS,COC,UL黄卡和物性表及加工参数.

TPEE 日本东丽 6347A特性:   

 

TPEE 日本东丽 其他型号报价:

TPEE

日本东丽

6347

 

15000

TPEE

日本东丽

6347A

 

22000

TPEE

日本东丽

7247

 

23000

TPEE

日本东丽

7247M

 

23000

TPEE

日本东丽

7247M HB582

40000

TPEE

日本东丽

7247R-F

 

48000

TPEE

日本东丽

7247W

 

35000

TPEE

日本东丽

7277

 

23000

TPEE

日本东丽

G3548L

 

26500

TPEE

日本东丽

HDT576

 

40000

TPEE

日本东丽

HTC2551W

 

40000

TPEE

日本东丽

HTC2751

 

39000

TPEE

日本东丽

SB704W BK

 

30000

                                                                 

TPEE 日本东丽 6347A :2017年4月24日,日本东丽公司发布消息称,东丽公司5种聚酯纤维、尼龙面料的超强性能再次获得日本宇宙航空研究开发所(JAXA)的高度评价,并通过JAXA创立的JAXACOSMODE品牌认证。

此次通过JAXACOSMODE品牌认证的5种材料分别是具有极高舒适伸展性能的PRIMEFLEX?、强力吸汗速干的FIELDSENSOR?、耐脏易清洁的TECHNOCLEAN?、具有防静电功能的SUPERPAREL?以及带超高导电性能的纤维材料LUANA?。这些材料改善了航空舱内宇航员们着装的舒适性和安全性,受到日本宇宙航空研究开发机构的高度评价。此次通过JAXACOSMODE品牌的认证,无疑将再次推动航空技术民用化的进程。东丽公司表示,今后采用这5种材料生产的商品将会附上JAXACOSMODE的标签,也会在店铺介绍中详细标识出来。东丽公司预计此类商品2017年销售额为1.2亿日元,2020年计划达到3.5亿日元。
据悉,JAXACOSMODE是日本宇宙航空研究开发机构(JAXA)与民间拥有尖端技术的企业合作开发的商品品牌,2008年由JAXA创立,旨在在日常生活中向人们传达宇宙与天空的魅力。东丽早在2012年就与JAXA合作开发出具有除臭功能的新面料MONSIEURON?,也已获得JAXACOSMODE品牌认证。东丽意欲在长期经营目标“AP-GrowthTORAY2020”中,进一步树立世界尖端材料厂商形象,利用高分子化学、有机合成化学等领域的核心技术加速开发超高性能的尖端新材料。

 

TPEE 日本东丽 6347A :oray Industries, Inc. (head office: Chuo-ku, Tokyo; President: Akihiro Nikkaku; hereinafter referred to as "Toray") today announced that on March 30, 2017 it received approval for an additional orally disintegrating tablets formulation (REMITCH® OD Tablets 2.5 μg; hereinafter referred to as the "OD tablets") of REMITCH® CAPSULES 2.5 μg. Toray already has manufacturing and marketing approval for the drug, which is being distributed by Torii Pharmaceutical Co., Ltd. (head office: Chuo-ku, Tokyo; President: Shoichiro Takagi; hereinafter referred to as "Torii Pharmaceutical") as a treatment of pruritus in hemodialysis and chronic liver disease patients (use only when sufficient efficacy is not obtained with the existing therapies or treatments) in Japan (tie-up with Japan Tobacco Inc. (head office: Minato-ku, Tokyo; President: Mitsuomi Koizumi)) and is being promoted by Sumitomo Dainippon Pharma Co., Ltd. (head office: Osaka; President: Masayo Tada; hereinafter referred to as "Sumitomo Dainippon Pharma") for treating pruritus in chronic liver disease patients. The OD tablets, for which Toray has obtained the approval this time, can be taken with or without water and therefore is convenient for the patients whose swallowing capabilities have deteriorated or those who have restrictions on water intake and is expected to lead to improved drug intake compliance.   The four companies expect that the approval of additional formulation would offer a new treatment option and significantly contribute to the treatment of pruritus in hemodialysis and chronic liver disease patients.   The outline of REMITCH® OD Tablets 2.5μg is as follows:

[Product outline]

Product name

:

REMITCH® OD Tablets 2.5μg

Generic name

:

Nalfurafine hydrochloride

Indications

:

Improvement of pruritus in the following patients (use only when sufficient efficacy is not obtained with the existing therapies or treatments): hemodialysis patients, patients with chronic liver disease

Dosage and administration

:

The recommended dose for adults is 2.5μg of nalfurafine hydrochloride once daily, administered orally after an evening meal or before bedtime. The dose can be increased in accordance with the symptoms, the maximum dose is 5μg once daily

Date of approval for the additional formulation : March 30, 2017

Manufacturer/distributor

:

Toray Industries, Inc.


REMITCH® OD Tablets 2.5μg
The agent is the worlds first highly selective kappa opioid receptor agonist developed by Toray and has been distributed in Japan since March 2009 by Torii Pharmaceutical as a treatment for pruritus in hemodialysis patients. It controls itching based on a mechanism that is different from antihistamines and anti-allergy drugs and, therefore, was developed with the expectation that it would be effective for pruritus which could not be controlled with existing treatments. In addition, REMITCH® was also approved for treating pruritus in chronic liver disease patients in May 2015, and Sumitomo Dainippon Pharma formed an alliance promoting it for this indication.
The agent had been available only as a soft capsule until now. Toray had been developing the OD tablets version, which can be administered without water, so as to improve convenience for patients whose swallowing capabilities have deteriorated or those who have restrictions on water intake.

 

如需了解更多关于TPEE 日本东丽 6347A 的详细信息,欢迎致电联系。


零风险购货10天无理由退换货

为了更好的服务客户,我公司现推出零风险采购方案,你在我公司购买的货物只要发货后10天内。你对货物有任何不满意都可以提出退换申请,在货物未拆封,不影响二次销售的情况下,我司将给你办理退换手续并承担运费,为你免去任何担忧。

TPEE 日本东丽 6347A今日新闻:

河北贵航鸿图汽车零部件有限公司是一家专业开发和生产汽车密封系列产品的企业,2016年被认定为国家级高新技术企业,2017年被省科技厅认定为“科技小巨人企业”;2016年和湖北省化学研究院、武汉理工大学共同研发了TPEE改性热塑性弹性体密封条。目前主要为上汽通用五菱、一汽集团、东风汽车有限公司、东风悦达起亚、北汽、东风柳汽、上海汽车等汽车企业批量供货,并与这些汽车生产厂家实现同步开发,车型涵盖SUV类、轿车类、重卡类等。


该公司其他信息
最新供求信息 企业产品推荐

暂无产品
  在线询盘/留言 请仔细填写准确及时的联系到你!  
您的姓名:
* 预计需求数量: *
联系手机:
*  移动电话或传真:
电子邮件:
* 所在单位:
咨询内容:
*
           您要求厂家给您提供:
  • 规格,型号
  • 价格及付款条件
  • 产品目录
  • 最低订货量
  • 运送资料
  • 提供样本
  • 库存情况
  • 包装材料